Evidence map›Paper›PMID 32703953›Full record

ReviewNature reviews. Disease primers2020

Hodgkin lymphoma.

Joseph M Connors, Wendy Cozen, Christian Steidl, Antonino Carbone, Richard T Hoppe, Hans-Henning Flechtner, Nancy L Bartlett

Erratum issued Registry-linked trialAbstract readReview
PubMed Publisher
In one paragraph

Review in Nature reviews. Disease primers, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT05490953 (Enhancing Effect on Tumour Apoptosis With the Combined Use of Pentoxifylline Plus Chemotherapeutical Agents in Pediatrics and AYA Patients With Hodgkin´s Lymphoma), which is not on this map. Cited by 131 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
131citing papers in PubMed, 4 pooled it
15.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05490953 phase4unknown statusnot on this mapstarted 2022, after this paper: background citation

Enhancing Effect on Tumour Apoptosis With the Combined Use of Pentoxifylline Plus Chemotherapeutical Agents in Pediatrics and AYA Patients With Hodgkin´s Lymphoma

TypeinterventionalSponsorUniversity of GuadalajaraRan2022 to 2024Enrolled30ConditionsHodgkin LymphomaArmsPentoxifylline, Placebo
3 · Its place in the literature

Who cites it

131 citing papers in PubMed, 4 syntheses or guidelines pooled it, 209 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Review
  19. Article
  20. Review

71 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 6 institutions in 4 countries.

Joseph M ConnorsBC Cancer Centre for Lymphoid Cancer, Vancouver, BC, Canada. jomiconnors@gmail.com.
Wendy CozenDepartment of Preventive Medicine, Center for Genetic Epidemiology, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA.
Christian SteidlBC Cancer Centre for Lymphoid Cancer, Vancouver, BC, Canada.
Antonino CarboneDivision of Pathology, Centro di Riferimento Oncologico (CRO), National Cancer Institute, Aviano, Italy.
Richard T HoppeDepartment of Radiation Oncology, Stanford University, Stanford, CA, USA.
Hans-Henning FlechtnerDepartment of Child and Adolescent Psychiatry, Otto-von-Guericke University, Magdeburg, Germany.
Nancy L BartlettDivision of Oncology, Washington University School of Medicine, St Louis, MO, USA.
Spinal Cord Injury BC · CACentro di Riferimento Oncologico · ITOtto-von-Guericke University Magdeburg · DEStanford University · USUniversity of Southern California · USWashington University in St. Louis · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hodgkin lymphoma (HL) is a B cell lymphoma characterized by few malignant cells and numerous immune effector cells in the tumour microenvironment. The incidence of HL is highest in adolescents and young adults, although HL can affect elderly individuals. Diagnosis is based on histological and immunohistochemical analyses of tissue from a lymph node biopsy; the tissue morphology and antigen expression profile enable classification into one of the four types of classic HL (nodular sclerosis, mixed cellularity, lymphocyte-depleted or lymphocyte-rich HL), which account for the majority of cases, or nodular lymphocyte-predominant HL. Although uncommon, HL remains a crucial test case for progress in cancer treatment. HL was among the first systemic neoplasms shown to be curable with radiation therapy and multiagent chemotherapy. The goal of multimodality therapy is to minimize lifelong residual treatment-associated toxicity while maintaining high levels of effectiveness. Recurrent or refractory disease can be effectively treated or cured with high-dose chemotherapy followed by autologous haematopoietic stem cell transplantation, and prospective trials have demonstrated the potency of immunotherapeutic approaches with antibody-drug conjugates and immune checkpoint inhibitors. This Primer explores the wealth of information that has been assembled to understand HL; these updated observations verify that HL investigation and treatment remain at the leading edge of oncological research.

Indexed as

Age FactorsGenetic Diseases, InbornHerpesvirus 4, HumanHodgkin DiseaseHumansIncidenceNeoplasm Staging

Identifiers

PMID32703953
OpenAlexW4211103460

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.